Martin Birkhofer

1.0k total citations
20 papers, 802 citations indexed

About

Martin Birkhofer is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Martin Birkhofer has authored 20 papers receiving a total of 802 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Martin Birkhofer's work include Cancer Treatment and Pharmacology (5 papers), Chemotherapy-induced organ toxicity mitigation (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Martin Birkhofer is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Chemotherapy-induced organ toxicity mitigation (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Martin Birkhofer collaborates with scholars based in United States, Germany and Netherlands. Martin Birkhofer's co-authors include Kapil N. Bhalla, Bernard S. Goffe, Michael Goldfarb, Alan Menter, Karen Berry, Hans D. Ochs, Gerald G. Krueger, Garvin L. Warner, Peter S. Linsley and Cynthia Guzzo and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Martin Birkhofer

20 papers receiving 772 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martin Birkhofer United States 9 371 186 140 122 97 20 802
T Radaszkiewicz Austria 14 357 1.0× 117 0.6× 191 1.4× 136 1.1× 96 1.0× 27 643
S Sugai Japan 10 237 0.6× 142 0.8× 93 0.7× 72 0.6× 49 0.5× 31 592
Paloma Pérez‐Aciego Spain 15 561 1.5× 126 0.7× 62 0.4× 95 0.8× 53 0.5× 28 855
Michael E. Osband United States 16 378 1.0× 249 1.3× 71 0.5× 71 0.6× 29 0.3× 42 868
Mitsuo Okubo Japan 13 401 1.1× 126 0.7× 50 0.4× 111 0.9× 89 0.9× 44 667
Elana J. Bloom United States 13 347 0.9× 229 1.2× 189 1.4× 71 0.6× 151 1.6× 24 879
Keiko Hodohara Japan 16 276 0.7× 228 1.2× 223 1.6× 90 0.7× 39 0.4× 56 871
M. Bunce United Kingdom 16 594 1.6× 93 0.5× 122 0.9× 111 0.9× 34 0.4× 29 974
J.‐L. Pasquali France 13 348 0.9× 86 0.5× 93 0.7× 134 1.1× 145 1.5× 29 893
Bruce A. Robbins United States 17 287 0.8× 271 1.5× 68 0.5× 89 0.7× 147 1.5× 26 963

Countries citing papers authored by Martin Birkhofer

Since Specialization
Citations

This map shows the geographic impact of Martin Birkhofer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Birkhofer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Birkhofer more than expected).

Fields of papers citing papers by Martin Birkhofer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Birkhofer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Birkhofer. The network helps show where Martin Birkhofer may publish in the future.

Co-authorship network of co-authors of Martin Birkhofer

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Birkhofer. A scholar is included among the top collaborators of Martin Birkhofer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Birkhofer. Martin Birkhofer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Anderson, Peter M., Minal Barve, Jonathan Gill, et al.. (2017). A bi-shRNAfurin and GMCSF engineered autologous tumor cell immunotherapy vs. gemcitabine + docetaxel for Ewing sarcoma and with cryoablation in Ewing family tumors.. Journal of Clinical Oncology. 35(15_suppl). TPS11079–TPS11079. 1 indexed citations
2.
Oh, Jonathan, Minal Barve, Devansu Tewari, et al.. (2017). Clinical trial in progress: A phase 3 study of maintenance bi-shRNA-furin/GM-CSF-expressing autologous tumor cell vaccine in women with stage IIIb-IV high-grade epithelial ovarian cancer.. Journal of Clinical Oncology. 35(15_suppl). TPS5604–TPS5604. 4 indexed citations
3.
Meropol, Neal J., et al.. (2001). Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Cancer Chemotherapy and Pharmacology. 47(3). 282–282. 4 indexed citations
4.
LaCreta, Frank, et al.. (2000). A Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Gatifloxacin in Healthy Adult Men. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 20(6P2). 49S–58S. 51 indexed citations
5.
Meropol, Neal J., et al.. (1999). Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Cancer Chemotherapy and Pharmacology. 43(3). 221–226. 15 indexed citations
6.
Lebwohl, Mark, Cynthia Guzzo, Brian V. Jegasothy, et al.. (1999). CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. Journal of Clinical Investigation. 103(9). 1243–1252. 473 indexed citations
7.
Meropol, N J, et al.. (1997). Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.. PubMed. 11(9 Suppl 10). 22–5. 5 indexed citations
8.
Huizing, Manon, Laurence J. van Warmerdam, Hilde Rosing, et al.. (1997). Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.. Journal of Clinical Oncology. 15(5). 1953–1964. 65 indexed citations
9.
Olver, Ian, Michael Green, Guy C. Toner, et al.. (1995). A Phase II Trial of Zeniplatin in Metastatic Melanoma. American Journal of Clinical Oncology. 18(1). 56–58. 8 indexed citations
10.
Budman, Daniel R., Martin Birkhofer, Stuart M. Lichtman, et al.. (1995). Pharmacokinetic evaluation of zeniplatin in humans. Cancer Chemotherapy and Pharmacology. 36(1). 35–40. 1 indexed citations
11.
Markman, Maurie, Linda C. DeMarco, Martin Birkhofer, et al.. (1993). Phase II trial of zeniplatin (CL 286 558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy. Journal of Cancer Research and Clinical Oncology. 119(4). 234–236. 5 indexed citations
12.
Zimmer, Aline, Edward A. Silverstein, Stewart Spies, et al.. (1993). A Phase I Escalating-Dose Safety, Dosimetry and Efficacy Study of Radiolabeled Monoclonal Antibody LYM-1. PubMed. 8(1). 3–16. 26 indexed citations
13.
Willemse, P.H.B., Jourik A. Gietema, Nanno H. Mulder, et al.. (1993). Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex. European Journal of Cancer. 29(3). 359–362. 8 indexed citations
14.
Bhalla, Kapil N., Martin Birkhofer, Z Arlin, et al.. (1991). Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells.. PubMed. 19(7). 669–73. 9 indexed citations
15.
Bhalla, Kapil N., et al.. (1991). A Phase I Study of a Combination of Allopurinol, 5-Fluorouracil and Leucovorin Followed by Hydroxyurea in Patients with Advanced Gastrointestinal and Breast Cancer. American Journal of Clinical Oncology. 14(6). 509–513. 3 indexed citations
16.
17.
18.
Bhalla, Kapil N., Martin Birkhofer, Steven Grant, & G. Graham. (1989). The effect of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) on 3'-azido-3'-deoxythymidine (AZT)-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells.. PubMed. 17(1). 17–20. 47 indexed citations
19.
Bhalla, Kapil N., et al.. (1988). Continuously Administered 2',2'-Difluorodeoxycytidine (Dfdc) and Deoxycytidine (Dcyd) - a Potentially Selective Cyto-Toxic Regimen Toward Human-Leukemic Myeloid Progenitors in Culture. Queensland's institutional digital repository (The University of Queensland). 29. 348–348. 2 indexed citations
20.
Bhalla, Kapil N., Martin Birkhofer, Z Arlin, et al.. (1988). Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells.. PubMed. 2(12). 810–3. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T Radaszkiewicz Breakdown of academic impact, for papers by S Sugai Breakdown of academic impact, for papers by Paloma Pérez‐Aciego Breakdown of academic impact, for papers by Michael E. Osband Breakdown of academic impact, for papers by Mitsuo Okubo Breakdown of academic impact, for papers by Elana J. Bloom Breakdown of academic impact, for papers by Keiko Hodohara Breakdown of academic impact, for papers by M. Bunce Breakdown of academic impact, for papers by J.‐L. Pasquali Breakdown of academic impact, for papers by Bruce A. Robbins
Rankless by CCL
2026